March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Advanced Glycation End Products Upregulate CD40 in Endothelial Cells and Muller Cells and Promote CD40-dependent Pro-inflammatory Responses
Author Affiliations & Notes
  • Jose-Andres C. Portillo
    Medicine/Infectious Diseases,
    Case Western Reserve University, Cleveland, Ohio
  • Jennifer A. Greene
    Medicine/Infectious Diseases,
    Case Western Reserve University, Cleveland, Ohio
  • Ram H. Nagaraj
    Ophthalmology and Visual Sciences,
    Case Western Reserve University, Cleveland, Ohio
  • Carlos Subauste
    Medicine, Case Western Reserve Univ Sch of Med, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  Jose-Andres C. Portillo, None; Jennifer A. Greene, None; Ram H. Nagaraj, None; Carlos Subauste, None
  • Footnotes
    Support  NIH Grant EY019250 (C.S.S), 5-2008-233 and 1-2009-204 from the JDRF (C.S.S), Helen Weil Ross Memorial Grant from the Dietrich Diabetes Research Institute (C.S.S), NIH Grant P30 EY11373,
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2430. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jose-Andres C. Portillo, Jennifer A. Greene, Ram H. Nagaraj, Carlos Subauste; Advanced Glycation End Products Upregulate CD40 in Endothelial Cells and Muller Cells and Promote CD40-dependent Pro-inflammatory Responses. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2430.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Advanced glycation end products (AGEs) play an important role in the pathogenesis of vascular complications of diabetes. These disorders have an important inflammatory component. CD40 is a member of the TNF receptor superfamily that promotes various pro-inflammatory responses. We examined the effects of AGEs on CD40 expression on endothelial cells and Muller cells as well as on CD40-mediated pro-inflammatory responses.

Methods: : Human primary endothelial cells and Muller cells were incubated with methyl glyoxal (MGO)-modified fibronectin, MGO-modified human serum albumin or appropriate controls. CD40 expression was assessed by flow cytometry. Control or AGE-treated cells were incubated with or without CD154 (CD40 ligand). Expression of ICAM-1 and MCP-1 were examined by flow cytometry or ELISA respectively.

Results: : Incubation with MGO induced expression of AGEs in fibronectin as assessed by immunofluorescence using anti-antibodies against hydroimidazolone or argpyrimidine. MGO-modified fibronectin as well as MGO-modified human serum albumin upregulated CD40 on primary human retinal endothelial cells, aortic endothelial cells and Muller cells. CD40 upregulation was of functional relevance. Compared to endothelial cells incubated with control fibronectin, endothelial cells incubated with MGO-modified fibronectin exhibited higher upregulation of ICAM-1 and MCP-1 production in response to CD154. Similarly, Muller cells incubated with MGO-modified fibronectin produced higher amounts of MCP-1 and expressed higher levels of ICAM-1 after CD154 stimulation.

Conclusions: : These studies revealed that AGEs are modulators of CD40 expression in endothelial cells and Muller cells and enhance CD40-dependent pro-inflammatory responses.

Keywords: retina • inflammation • retinal glia 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×